Briciclib (ON 014185) sodium is a eukaryotic translation initiation factor 4E (eIF4E) inhibitor. Briciclib sodium exhibits broad-spectrum anti-cancer activity, including in mantle cell leukemia, breast cancer, gastric cancer, and esophageal cancer cells. Briciclib sodium reduces the expression of cyclin D1 and c-Myc, and enhances the expression of P53 and Cleaved Caspase 3 pro-apoptotic proteins. Briciclib sodium can be used for the study of hematological system tumors and solid tumors.

BRD9 ligand-13 is a BRD9 ligand that can be used for the synthesis of PROTACs, such as PROTAC BRD9 Degrader-8.

BRD4-IN-12 is a potent and orally active BRD4 inhibitor with an IC50 of 7.9 nM. BRD4-IN-12 downregulates the expression of c-MYC, BCL-2, CDK4 and upregulates p21. BRD4-IN-12 inhibits tumor cell proliferation and promotes apoptosis. BRD4-IN-12 exhibits excellent antitumor effects in the HCT-116 colorectal cancer xenograft model. BRD4-IN-12 can be used for the study of colorectal cancer (CRC).

BRD4 ligand 15 (compound 5) is a BRD4 ligand and alkyne-modified chalcone derivative, which serves as a building block for the synthesis of BRD4-targeting PROTAC TKP-5.

Br-C1-CONH-C5-CO-Val-Cit-PAB-MMAE (compound 62) is a drug-linker conjugate that contains a monomethyl auristatin E (MMAE) drug moiety, which is linked to a bromoacetamide-containing extension unit via a valine-citrulline (Val-Cit) dipeptide and a self-immolative p-aminobenzyl (PAB) spacer. Br-C1-CONH-C5-CO-Val-Cit-PAB-MMAE is applicable to the research of breast cancer, anaplastic large cell lymphoma and lung adenocarcinoma.

Bradanicline (TC-5619) tosylate is an orally active agonist of α7 nAChR with moderate blood-brain barrier penetration. Bradanicline tosylate exhibits high affinity and subtype selectivity for human α7 nAChR. Bradanicline tosylate possesses antitussive activity that depends on sustained receptor binding and activation. Bradanicline tosylate requires systemic administration to dose-dependently inhibit cough induced by citric acid, bradykinin and inhaled nicotine. Bradanicline tosylate is well tolerated in preclinical studies and is widely used in research related to chronic refractory cough.

BrAc-Galactose-Sar-N-Me-alanine-DM1 (compound 11) is a drug-linker conjugate for ADC, which can be conjugated with the anti-TM4SF1 antibody (e.g., AGX-A07 for the synthesis of ADC.

BrAA-glycine-BG-PAB-Exatecan (Compound LD-11) is an Drug-Linker Conjugates for ADC, consisting of Exatecan and a linker. BrAA-glycine-BG-PAB-Exatecan can be conjugated with anti-ROR1 antibodies to form an ADC.\n

BR103354 is an orally active, selective fibroblast activation protein (FAP) inhibitor with an IC50 value of 14 nM against hFAP. BR103354 restores the levels of phosphorylated ERK and Glut1 that are reduced by co-treatment with hFGF21 and FAP, decreases non-fasting blood glucose concentrations, improves glucose tolerance, and reduces hepatic triglyceride content. BR103354 ameliorates hepatic steatosis and hepatic fibrosis. BR103354 can be used in the research of type 2 diabetes and non-alcoholic steatohepatitis.

BODIPY TMR PI(4,5)P2 ester ammonium is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.

BODIPY TMR Lyso PS ester ammonium is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.

BODIPY TMR Lyso PI ester ammonium is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.

BODIPY TMR Lyso PE ester is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.

BODIPY TMR Lyso PA ester ammonium is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.

BMY-30047 is a retinoic acid derivative. BMY-30047 has topical retinoid activity. BMY-30047 has relative low local and systemic toxicity.

BMS-856 is a 17β-HSD3 inhibitor. BMS-856 inhibits enzymatic activity of 17β-HSD3, with IC50s of 60 and 300 nM respectively in the enzyme and whole cell assays.

BMS-520 is a potent, orally active and selective sphingosine-1-phosphate 1 (S1P1) agonist with an EC50 of 0.47nM. BMS-520 shows ~3400-fold selectivity over S1P3. BMS-520 demonstrates impressive efficacy in a rat model of arthritis and in a mouse experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis. BMS-520 can be used for arthritis and EAE research.

BMS-142 is a PDL1 inhibitor (IC50 = 96.7 nM) (kd = 13.2 nM). BMS-142 can reduce the survival rate of acute T-lymphoblastic leukemia cells and ovarian cancer cells. BMS-142 can be used in research on cancers such as acute T-lymphoblastic leukemia and ovarian cancer.

BMS-135 is a potenr, selective and ATP-competitive casein kinase 2 (CK2) inhibitor with IC50 of 0.8 and 0.3 nM for CK2αandCK2α′ isoforms. BMS-135 can simulate the structure of ATP and bind to the active pocket of CK2, thereby inhibiting its serine/threonine phosphorylation function. BMS-135 can inhibit cells proliferation and shows anti-tumor effect. BMS-135 can be used for research of colon cancer.

BMS-103 is a PDL1 inhibitor (IC50 = 79.1 nM) (kd = 44 nM). BMS-103 reduces the survival rate of acute T-lymphoblastic leukemia cells and ovarian cells. BMS-103 can be used in research on acute T-lymphoblastic leukemia and cancers such as ovarian cancer.

BMMP is an anti-HIV-1 agent and hnRNP M modulator. BMMP modulates hnRNP M function to suppress CD44 mRNA expression. BMMP induces abnormal uncoating of the HIV viral core at the post-entry step. BMMP suppresses migration of TGF-β-stimulated lung carcinoma cells. BMMP suppresses HIV-1 reverse transcription and replication without inhibiting virion release. BMMP exerts anti-HIV-1 activity via a mechanism distinct from CA protein-binding heterocyclic compounds. BMMP can be used for the research of human immunodeficiency virus infection and non-small cell lung cancer.

BLT1-IN-1 is an orally active and selective BLT1 inhibitor with an IC50 of 8.7 nM and a Kd of 121 nM. BLT1-IN-1 exerts protective effects against acute lung injury and sepsis in in vivo models. BLT1-IN-1 can be used in research related to acute lung injury and sepsis.

BL20-MMAE is an antibody-drug conjugate targeting ROR1, which is formed by conjugating an anti-ROR1 antibody with the Auristatin payload MMAE via a BL20 linker.

BL-1021 is an orally active ion channel blocker. BL-1021 significantly reduces symptoms of neuropathic pain without noticeable sedation or cardiac arrhythmias. BL-1021 can be used in the research of acute and chronic pain.

BKT300 is a potent and selective protein regulator of cytokinesis 1 (PRC1) inhibitor. BKT300 inhibits PRC1 dephosphorylation at T481, disrupts actin and microtubule formation, induces G2/M cell cycle arrest, triggers mitotic catastrophe, and promotes apoptosis, thereby inhibiting proliferation and migration of acute myeloid leukemia (AML) cells while sparing normal cells. BKT300 inhibits tumor growth in mouse xenograft AML models. BKT300 can be used for the research of AML[1].

BKI 1708 is a potent and orally active calcium-dependent protein kinase 1 (CDPK1) inhibitor (IC50 = 0.7 nM). BKI 1708 exhibits potent activity against Neospora (IC50 = 481 nM) and Toxoplasma (IC50 = 122 nM). BKI-1708 induces the formation of multinucleated complexes. BKI-1708 efficiently inhibits vertical transmission of both parasites and increases pup survival in mice.

Bis-Mal-Lysine-PEG4-DBCO (CGBS-13) is a linker for AOC drugs and can be used to synthesize AOC drugs that inhibit DMPK gene expression.

Bisdisulizole disodium is an organic chromophore with large near UV absorption cross section. Solutions of Bisdisulizole disodium dissolved in polar solvents show a strong, broad UV absorption feature centered at 340 nm.

Bilirubin ditaurine (BR-DT) is a mimetic compound of conjugated bilirubin. Bilirubin ditaurine can completely prevent the oxidation of phosphatidylcholine induced by reactive oxygen species in multilayer liposomes or micelles. Bilirubin ditaurine does not significantly decompose 18:2-OOH on its own, but it can greatly accelerate the decomposition of 18:2-OOH catalyzed by copper ions. Bilirubin ditaurine can be used to study the detoxification effect of conjugated bilirubin.

BET-IN-29 (Compound 1) is a bromodomain and the terminal motif (BET) inhibitor. BET-IN-29 can be used for the study of cancer, inflammation, metabolism, neurological diseases, and infectious diseases.